Meeting
2022 ASCO Annual Meeting
A phase 1/2 dose-escalation and dose-expansion study of ZN-c3 in combination with gemcitabine in adult and pediatric subjects with relapsed or refractory osteosarcoma.
Authors
Viswatej Avutu
Memorial Sloan Kettering Cancer Center, New York, NY
Viswatej Avutu , Emily K Slotkin , J Andrew Andrew Livingston , Sant P. Chawla , Joseph Gerald Pressey , Preeya Nandkumar , Cheng Zheng , Soamnauth Misir , Philippe Pultar , Dimitris Voliotis , Katherine Anne Thornton , Noah Federman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Bone Tumors
Clinical Trial Registration Number
NCT04833582
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS11584)
DOI
10.1200/JCO.2022.40.16_suppl.TPS11584
Abstract #
TPS11584
Poster Bd #
487a
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase 2 trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT).
First Author: Yago Nieto
Poster
2012 ASCO Annual Meeting
Phase II trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) for refractory germ-cell tumors (GCT).
First Author: Yago Nieto
Poster
2011 ASCO Annual Meeting
Phase II clinical trial of oxaliplatin and bevacizumab in refractory metastatic germ cell tumors (GCT).
First Author: A. Jain
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase 2 study of cabozantinib (Cabo) and pembrolizumab (Pembro) in metastatic gastric/gastroesophageal adenocarcinoma (mGEA) resistant or refractory to immune checkpoint inhibitors (ICI).
First Author: Farshid Dayyani